Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Impact of pitavastatin on high-sensitivity C-reactive protein and adiponectin in hypercholesterolemic patients with the metabolic syndrome: The PREMIUM Study
Tatsuaki Matsubara, Keiko Naruse, Takemi Arakawa, et al.
Journal of Cardiology (2012) Vol. 60, Iss. 5, pp. 389-394
Closed Access | Times Cited: 29

Showing 1-25 of 29 citing articles:

Fluvastatin for lowering lipids
Stephen P. Adams, Sarpreet S Sekhon, Michael Tsang, et al.
Cochrane library (2018) Vol. 2018, Iss. 3
Open Access | Times Cited: 65
Pitavastatin in cardiometabolic disease: therapeutic profile
L. Masana
Cardiovascular Diabetology (2013) Vol. 12, Iss. Suppl 1, pp. S2-S2
Open Access | Times Cited: 57
Could changes in adiponectin drive the effect of statins on the risk of new-onset diabetes? The case of pitavastatin
Lorenzo Arnaboldi, Alberto Corsini
Atherosclerosis Supplements (2015) Vol. 16, pp. 1-27
Closed Access | Times Cited: 48
Pitavastatin for lowering lipids
Stephen P. Adams, Nima Alaeiilkhchi, James M Wright
Cochrane library (2020) Vol. 2020, Iss. 7
Open Access | Times Cited: 33
Effect of Pitavastatin Compared with Atorvastatin andRosuvastatin on New-Onset Diabetes Mellitus in PatientsWith Acute Myocardial Infarction
Jah Yeon Choi, Cheol Ung Choi, Soon-Young Hwang, et al.
The American Journal of Cardiology (2018) Vol. 122, Iss. 6, pp. 922-928
Closed Access | Times Cited: 34
The place of original pitavastatin in primary and secondary prevention of cardiovascular diseases. Interdisciplinary Expert Consensus of the Russian Society of Cardiology, the National Atherosclerosis Society, the Russian Society of Cardiosomatic Rehabilitation and Secondary Prevention, and the Russian Association of Endocrinologists
М. Г. Бубнова, А. S. Galyavich, М. В. Ежов, et al.
Cardiosomatics (2025)
Open Access
Association of homeostasis model assessment of insulin resistance, adiponectin, and low-grade inflammation with the course of the metabolic syndrome
Yusong Ding, Shugang Li, Rulin Ma, et al.
Clinical Biochemistry (2015) Vol. 48, Iss. 7-8, pp. 503-507
Closed Access | Times Cited: 26
Differential Metabolic Actions of Specific Statins: Clinical and Therapeutic Considerations
Soo Lim, Ichiro Sakuma, Michael J. Quon, et al.
Antioxidants and Redox Signaling (2013) Vol. 20, Iss. 8, pp. 1286-1299
Open Access | Times Cited: 20
Independent and joint effects of high-sensitivity c-reactive protein and hypoalbuminemia on long-term all-cause mortality among coronary artery disease: a prospective and multicenter cohort study
Haozhang Huang, Yaren Yu, Liling Chen, et al.
BMC Cardiovascular Disorders (2021) Vol. 21, Iss. 1
Open Access | Times Cited: 15
Supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial—Rationale and design
Yasuhiko Sakata, Kotaro Nochioka, Masanobu Miura, et al.
Journal of Cardiology (2013) Vol. 62, Iss. 1, pp. 31-36
Open Access | Times Cited: 19
Biological and other health related correlates of long-term life dissatisfaction burden
Teemu Rissanen, Soili M. Lehto, Jukka Hintikka, et al.
BMC Psychiatry (2013) Vol. 13, Iss. 1
Open Access | Times Cited: 16
Clinical Benefits of Pitavastatin: Focus On Patients With Diabetes Or at Risk of Developing Diabetes
Vivencio Barrios, Carlos Escobar
Future Cardiology (2016) Vol. 12, Iss. 4, pp. 449-466
Closed Access | Times Cited: 14
Impact of preprocedural high-sensitive C-reactive protein levels on long-term clinical outcomes of patients with stable coronary artery disease and chronic kidney disease who were treated with drug-eluting stents
Manabu Ogita, Katsumi Miyauchi, Takatoshi Kasai, et al.
Journal of Cardiology (2015) Vol. 66, Iss. 1, pp. 15-21
Open Access | Times Cited: 13
PROPIT: A PROspective comparative clinical study evaluating the efficacy and safety of PITavastatin in patients with metabolic syndrome
Sung Hee Choi, Soo Lim, Eun Shil Hong, et al.
Clinical Endocrinology (2014) Vol. 82, Iss. 5, pp. 670-677
Closed Access | Times Cited: 13
Differential Diabetogenic Effect of Pitavastatin and Rosuvastatin, <i>in vitro</i> and <i>in vivo </i>
Yongin Cho, Hyangkyu Lee, Hyun Ki Park, et al.
Journal of Atherosclerosis and Thrombosis (2019) Vol. 27, Iss. 5, pp. 429-440
Open Access | Times Cited: 10
Clinical efficacy and safety of statin treatment after carotid artery stenting
Lingya Qiao, Shibo Wang, Qiang Jia, et al.
Artificial Cells Nanomedicine and Biotechnology (2019) Vol. 47, Iss. 1, pp. 3110-3115
Open Access | Times Cited: 7
Current perspectives on the use of statins in the treatment of dyslipidaemic patients: focus on pitavastatin
Lâle Tokgözoğlu, José Luis Zamorano
Drugs in Context (2020) Vol. 9, pp. 1-11
Open Access | Times Cited: 7
New Aspects of Cellular Cholesterol Regulation on Blood Glucose Control—Review and Perspective on the Impact of Statin Medications on Metabolic Health
Brian A. Grice, Jeffrey S. Elmendorf
US Endocrinology (2017) Vol. 13, Iss. 02, pp. 63-63
Open Access | Times Cited: 6
Searching the place of pitavastatin in the current treatment of patients with dyslipidemia
Vivencio Barrios, Carlos Escobar, José Luis Zamorano
Expert Review of Cardiovascular Therapy (2013) Vol. 11, Iss. 12, pp. 1597-1612
Closed Access | Times Cited: 4
Effects of pitavastatin on HDL metabolism
Ken Kishida, Tohru Funahashi, Iichiro Shimomura
Clinical Lipidology (2013) Vol. 8, Iss. 1, pp. 55-68
Closed Access | Times Cited: 4
Do statins reduce the mortality rate in stroke patients treated with systemic thrombolysis in a 5-year
Toralf Brüning, Mohamed Al‐Khaled
Neural Regeneration Research (2021) Vol. 16, Iss. 9, pp. 1807-1807
Open Access | Times Cited: 4
Combined impact of residual inflammatory risk and chronic kidney disease on long-term clinical outcomes in patients undergoing percutaneous coronary intervention
Ryota Nishio, Tomotaka Dohi, Mitsuhiro Takeuchi, et al.
Journal of Cardiology (2021) Vol. 79, Iss. 4, pp. 509-514
Open Access | Times Cited: 4
Repurposing Pitavastatin and L-Glutamine: Replenishing β-Cells in Hyperlipidemic Type 2 Diabetes Mouse Model
Sayantani Pramanik Palit, Roma Patel, Nishant Parmar, et al.
Life (2023) Vol. 13, Iss. 4, pp. 929-929
Open Access | Times Cited: 1
Interdisciplinary Expert Consensus: the place of original pitavastatin in primary and secondary prevention of cardiovascular diseases
М. Г. Бубнова, А. S. Galyavich, М. В. Ежов, et al.
Russian Journal of Cardiology (2024) Vol. 29, Iss. 11, pp. 6148-6148
Open Access
The effect of some statins on Glucose blood levels in experimental animals
Nour Abboud, Rana Makhous
Research Journal of Pharmacy and Technology (2022), pp. 2661-2666
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top